Article
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 2013
Dingemans Anne-Marie C, Mellema Wouter W, Groen Harry J M, van Wijk Atie, Burgers Sjaak A, Kunst Peter W A, Thunnissen Erik, Heideman Danielle A M, Smit Egbert F
Abstract excerpt
PURPOSE: Sorafenib inhibits the Ras/Raf pathway, which is overactive in cancer patients with a KRAS mutation. We hypothesized that patients with non-small cell lung cancer (NSCLC) with KRAS mutation will benefit from treatment with sorafenib. EXPERIMENTAL DESIGN: In this phase II study, patients with KRAS-mutated, stage IIIb or IV NSCLC that progressed after at least one platinum-containing regimen were treated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.